Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis
- Autores
- Perrone, Maria Cecilia; Graña, Karen Daniela; Werbach, Andrea; Rodriguez, Maria Jimena; Riggio, Marina; Enrico, Diego; Mando, Pablo; Amat, Mora; Novaro, Virginia
- Año de publicación
- 2021
- Idioma
- inglés
- Tipo de recurso
- documento de conferencia
- Estado
- versión publicada
- Descripción
- PI3K/AKT/mTOR pathway is frequently altered in breast tumors and has consequently become a promising therapeutic target; therefore, novel biomarkers are in need. In luminal breast cancer cell lines, we have previously found that AKT isoforms play distinct roles in tumor progression, with AKT1 promoting cell proliferation and AKT2 favoring cell migration and invasion. To further investigate the potential use of these proteins as breast cancer progression biomarkers, we analyzed tumor histology and expression of AKT1, AKT2 and downstream S6 phosphorylation (pS6) by immunohistochemistry in 55 luminal breast cancer samples. Our results showed that AKT1 expression decreased with greater tumor stage and Nottingham score, while AKT2 and pS6 were associated with poor prognostic factors such as higher nuclear grade and Nottingham score. We next performed RT-qPCR to evaluate the tumor expression of AKT-associated microRNAs and found that miR-34a and miR-126 correlated positively with AKT1 and negatively with AKT2 expression. In sum, low AKT1 and high AKT2 and pS6 levels appear to be associated with poor prognostic markers in luminal breast tumors. Moreover, evaluating microRNAs that are differentially associated with AKT1 and AKT2 isoforms could potentially be an advantageous tool to assess tumor progression in patient blood samples.
Fil: Perrone, Maria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Graña, Karen Daniela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Werbach, Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Rodriguez, Maria Jimena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Riggio, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Fil: Enrico, Diego. Instituto Alexander Fleming; Argentina
Fil: Mando, Pablo. Instituto Alexander Fleming.; Argentina
Fil: Amat, Mora. Instituto Alexander Fleming.; Argentina
Fil: Novaro, Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina
Buenos Aires Breast Cancer Symposium
Buenos Aires
Argentina
Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”
Consejo Nacional de Investigaciones Científicas y Técnicas
Instituto de Biología y Medicina Experimental
Instituto de Fisiología, Biología Molecular y Neurociencias
Instituto de Investigaciones en Medicina Traslacional
Instituto de Nanosistemas
Universidad Austral
Universidad de Buenos Aires
Universidad Nacional de San Martín - Materia
-
PI3K/AKT PATHWAY
BREAST CANCER
BIOMARKERS - Nivel de accesibilidad
- acceso abierto
- Condiciones de uso
- https://creativecommons.org/licenses/by-nc-sa/2.5/ar/
- Repositorio
- Institución
- Consejo Nacional de Investigaciones Científicas y Técnicas
- OAI Identificador
- oai:ri.conicet.gov.ar:11336/152545
Ver los metadatos del registro completo
id |
CONICETDig_f6c47e926bcc094bdef1f2df38fd7132 |
---|---|
oai_identifier_str |
oai:ri.conicet.gov.ar:11336/152545 |
network_acronym_str |
CONICETDig |
repository_id_str |
3498 |
network_name_str |
CONICET Digital (CONICET) |
spelling |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosisPerrone, Maria CeciliaGraña, Karen DanielaWerbach, AndreaRodriguez, Maria JimenaRiggio, MarinaEnrico, DiegoMando, PabloAmat, MoraNovaro, VirginiaPI3K/AKT PATHWAYBREAST CANCERBIOMARKERShttps://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3https://purl.org/becyt/ford/3.1https://purl.org/becyt/ford/3PI3K/AKT/mTOR pathway is frequently altered in breast tumors and has consequently become a promising therapeutic target; therefore, novel biomarkers are in need. In luminal breast cancer cell lines, we have previously found that AKT isoforms play distinct roles in tumor progression, with AKT1 promoting cell proliferation and AKT2 favoring cell migration and invasion. To further investigate the potential use of these proteins as breast cancer progression biomarkers, we analyzed tumor histology and expression of AKT1, AKT2 and downstream S6 phosphorylation (pS6) by immunohistochemistry in 55 luminal breast cancer samples. Our results showed that AKT1 expression decreased with greater tumor stage and Nottingham score, while AKT2 and pS6 were associated with poor prognostic factors such as higher nuclear grade and Nottingham score. We next performed RT-qPCR to evaluate the tumor expression of AKT-associated microRNAs and found that miR-34a and miR-126 correlated positively with AKT1 and negatively with AKT2 expression. In sum, low AKT1 and high AKT2 and pS6 levels appear to be associated with poor prognostic markers in luminal breast tumors. Moreover, evaluating microRNAs that are differentially associated with AKT1 and AKT2 isoforms could potentially be an advantageous tool to assess tumor progression in patient blood samples.Fil: Perrone, Maria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Graña, Karen Daniela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Werbach, Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Rodriguez, Maria Jimena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Riggio, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaFil: Enrico, Diego. Instituto Alexander Fleming; ArgentinaFil: Mando, Pablo. Instituto Alexander Fleming.; ArgentinaFil: Amat, Mora. Instituto Alexander Fleming.; ArgentinaFil: Novaro, Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; ArgentinaBuenos Aires Breast Cancer SymposiumBuenos AiresArgentinaCentro de Educación Médica e Investigaciones Clínicas “Norberto Quirno”Consejo Nacional de Investigaciones Científicas y TécnicasInstituto de Biología y Medicina ExperimentalInstituto de Fisiología, Biología Molecular y NeurocienciasInstituto de Investigaciones en Medicina TraslacionalInstituto de NanosistemasUniversidad AustralUniversidad de Buenos AiresUniversidad Nacional de San MartínFundación Revista MedicinaKordon, Edith ClaudiaLanari, Claudia Lee MalvinaSimian, Marina2021info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/conferenceObjectSimposioJournalhttp://purl.org/coar/resource_type/c_5794info:ar-repo/semantics/documentoDeConferenciaapplication/pdfapplication/pdfapplication/pdfhttp://hdl.handle.net/11336/152545Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 30-300025-7680CONICET DigitalCONICETenginfo:eu-repo/semantics/altIdentifier/url/http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802021000600001&lng=es&nrm=iso&tlng=eninfo:eu-repo/semantics/altIdentifier/url/https://ba-bcs2020.com/info:eu-repo/semantics/altIdentifier/purl/http://ref.scielo.org/f45xp5Internacionalinfo:eu-repo/semantics/openAccesshttps://creativecommons.org/licenses/by-nc-sa/2.5/ar/reponame:CONICET Digital (CONICET)instname:Consejo Nacional de Investigaciones Científicas y Técnicas2025-09-10T13:23:04Zoai:ri.conicet.gov.ar:11336/152545instacron:CONICETInstitucionalhttp://ri.conicet.gov.ar/Organismo científico-tecnológicoNo correspondehttp://ri.conicet.gov.ar/oai/requestdasensio@conicet.gov.ar; lcarlino@conicet.gov.arArgentinaNo correspondeNo correspondeNo correspondeopendoar:34982025-09-10 13:23:04.399CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicasfalse |
dc.title.none.fl_str_mv |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis |
title |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis |
spellingShingle |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis Perrone, Maria Cecilia PI3K/AKT PATHWAY BREAST CANCER BIOMARKERS |
title_short |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis |
title_full |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis |
title_fullStr |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis |
title_full_unstemmed |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis |
title_sort |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis |
dc.creator.none.fl_str_mv |
Perrone, Maria Cecilia Graña, Karen Daniela Werbach, Andrea Rodriguez, Maria Jimena Riggio, Marina Enrico, Diego Mando, Pablo Amat, Mora Novaro, Virginia |
author |
Perrone, Maria Cecilia |
author_facet |
Perrone, Maria Cecilia Graña, Karen Daniela Werbach, Andrea Rodriguez, Maria Jimena Riggio, Marina Enrico, Diego Mando, Pablo Amat, Mora Novaro, Virginia |
author_role |
author |
author2 |
Graña, Karen Daniela Werbach, Andrea Rodriguez, Maria Jimena Riggio, Marina Enrico, Diego Mando, Pablo Amat, Mora Novaro, Virginia |
author2_role |
author author author author author author author author |
dc.contributor.none.fl_str_mv |
Kordon, Edith Claudia Lanari, Claudia Lee Malvina Simian, Marina |
dc.subject.none.fl_str_mv |
PI3K/AKT PATHWAY BREAST CANCER BIOMARKERS |
topic |
PI3K/AKT PATHWAY BREAST CANCER BIOMARKERS |
purl_subject.fl_str_mv |
https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 https://purl.org/becyt/ford/3.1 https://purl.org/becyt/ford/3 |
dc.description.none.fl_txt_mv |
PI3K/AKT/mTOR pathway is frequently altered in breast tumors and has consequently become a promising therapeutic target; therefore, novel biomarkers are in need. In luminal breast cancer cell lines, we have previously found that AKT isoforms play distinct roles in tumor progression, with AKT1 promoting cell proliferation and AKT2 favoring cell migration and invasion. To further investigate the potential use of these proteins as breast cancer progression biomarkers, we analyzed tumor histology and expression of AKT1, AKT2 and downstream S6 phosphorylation (pS6) by immunohistochemistry in 55 luminal breast cancer samples. Our results showed that AKT1 expression decreased with greater tumor stage and Nottingham score, while AKT2 and pS6 were associated with poor prognostic factors such as higher nuclear grade and Nottingham score. We next performed RT-qPCR to evaluate the tumor expression of AKT-associated microRNAs and found that miR-34a and miR-126 correlated positively with AKT1 and negatively with AKT2 expression. In sum, low AKT1 and high AKT2 and pS6 levels appear to be associated with poor prognostic markers in luminal breast tumors. Moreover, evaluating microRNAs that are differentially associated with AKT1 and AKT2 isoforms could potentially be an advantageous tool to assess tumor progression in patient blood samples. Fil: Perrone, Maria Cecilia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Graña, Karen Daniela. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Werbach, Andrea. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Rodriguez, Maria Jimena. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Riggio, Marina. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Fil: Enrico, Diego. Instituto Alexander Fleming; Argentina Fil: Mando, Pablo. Instituto Alexander Fleming.; Argentina Fil: Amat, Mora. Instituto Alexander Fleming.; Argentina Fil: Novaro, Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Instituto de Biología y Medicina Experimental. Fundación de Instituto de Biología y Medicina Experimental. Instituto de Biología y Medicina Experimental; Argentina Buenos Aires Breast Cancer Symposium Buenos Aires Argentina Centro de Educación Médica e Investigaciones Clínicas “Norberto Quirno” Consejo Nacional de Investigaciones Científicas y Técnicas Instituto de Biología y Medicina Experimental Instituto de Fisiología, Biología Molecular y Neurociencias Instituto de Investigaciones en Medicina Traslacional Instituto de Nanosistemas Universidad Austral Universidad de Buenos Aires Universidad Nacional de San Martín |
description |
PI3K/AKT/mTOR pathway is frequently altered in breast tumors and has consequently become a promising therapeutic target; therefore, novel biomarkers are in need. In luminal breast cancer cell lines, we have previously found that AKT isoforms play distinct roles in tumor progression, with AKT1 promoting cell proliferation and AKT2 favoring cell migration and invasion. To further investigate the potential use of these proteins as breast cancer progression biomarkers, we analyzed tumor histology and expression of AKT1, AKT2 and downstream S6 phosphorylation (pS6) by immunohistochemistry in 55 luminal breast cancer samples. Our results showed that AKT1 expression decreased with greater tumor stage and Nottingham score, while AKT2 and pS6 were associated with poor prognostic factors such as higher nuclear grade and Nottingham score. We next performed RT-qPCR to evaluate the tumor expression of AKT-associated microRNAs and found that miR-34a and miR-126 correlated positively with AKT1 and negatively with AKT2 expression. In sum, low AKT1 and high AKT2 and pS6 levels appear to be associated with poor prognostic markers in luminal breast tumors. Moreover, evaluating microRNAs that are differentially associated with AKT1 and AKT2 isoforms could potentially be an advantageous tool to assess tumor progression in patient blood samples. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021 |
dc.type.none.fl_str_mv |
info:eu-repo/semantics/publishedVersion info:eu-repo/semantics/conferenceObject Simposio Journal http://purl.org/coar/resource_type/c_5794 info:ar-repo/semantics/documentoDeConferencia |
status_str |
publishedVersion |
format |
conferenceObject |
dc.identifier.none.fl_str_mv |
http://hdl.handle.net/11336/152545 Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 30-30 0025-7680 CONICET Digital CONICET |
url |
http://hdl.handle.net/11336/152545 |
identifier_str_mv |
Potential use of PI3K pathway effectors and associated microRNAs as biomarkers of breast cancer prognosis; Buenos Aires Breast Cancer Symposium; Buenos Aires; Argentina; 2021; 30-30 0025-7680 CONICET Digital CONICET |
dc.language.none.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
info:eu-repo/semantics/altIdentifier/url/http://www.scielo.org.ar/scielo.php?script=sci_arttext&pid=S0025-76802021000600001&lng=es&nrm=iso&tlng=en info:eu-repo/semantics/altIdentifier/url/https://ba-bcs2020.com/ info:eu-repo/semantics/altIdentifier/purl/http://ref.scielo.org/f45xp5 |
dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
eu_rights_str_mv |
openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by-nc-sa/2.5/ar/ |
dc.format.none.fl_str_mv |
application/pdf application/pdf application/pdf |
dc.coverage.none.fl_str_mv |
Internacional |
dc.publisher.none.fl_str_mv |
Fundación Revista Medicina |
publisher.none.fl_str_mv |
Fundación Revista Medicina |
dc.source.none.fl_str_mv |
reponame:CONICET Digital (CONICET) instname:Consejo Nacional de Investigaciones Científicas y Técnicas |
reponame_str |
CONICET Digital (CONICET) |
collection |
CONICET Digital (CONICET) |
instname_str |
Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.name.fl_str_mv |
CONICET Digital (CONICET) - Consejo Nacional de Investigaciones Científicas y Técnicas |
repository.mail.fl_str_mv |
dasensio@conicet.gov.ar; lcarlino@conicet.gov.ar |
_version_ |
1842981272135139328 |
score |
12.48226 |